

## Technology Appraisal Committee Meeting Committee C

**Minutes:** **Confirmed**

**Date and Time:** **Wednesday 13 April 2016, 10:00 – 13:30**

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Chair Professor Andrew Stevens 2. Dr Ian Bernstein 3. David Chandler 4. Gail Coster 5. Dr Nigel Langford 6. Dr Iain Miller 7. Dr Paul Miller 8. Professor Eugene Milne 9. Professor Stephen O'Brien 10. Professor Andrew Renehan 11. Dr Peter Selby 12. Prof Matt Stevenson 13. Dr Paul Tappenden 14. Professor Robert Walton 15. Dr Judith Wardle	Present for all notes Present for all notes
-----------------	---	--

### In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephanie Yates	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Joanne Ekeledo	Administrator, National Institute for Health and Care Excellence	Present for all notes
Boglarka Mikundina	Technical Analyst,	Present for all notes

National Institute for  
Health and Care  
Excellence

Joanne Holden	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
---------------	---	-----------------------

**Non-public observers:**

Rumona Dickson	ERG representative	Present for notes 04 to 07
Angela Stainthorpe	ERG representative	Present for notes 04 to 07
Adrian Bagus	ERG representative	Present for notes 04 to 07
Dr Sanjay Popat	Clinical Expert	Present for notes 04 to 07
Dr Jesme Fox	Patient Expert	Present for notes 04 to 07
Mrs Carole Davies	Patient Expert	Present for notes 04 to 07
Anna Brett	NICE Observer	Present for all notes
Carl Boswell	NICE Observer	Present for all notes
Catherine Baron	NICE Observer	Present for all notes
Kate Moring	NICE Observer	Present for all notes
Nicola Hay	NICE Observer	Present for all notes
Mindaugas Štelemėkas	NICE Observer	Present for all notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer
2. Apologies were received from Dr Andrea Manca, Dr Anna O'Neill, Professor Kathryn Abel and Professor Rachel Elliott

**Any other Business**

3. None

**Appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer**

## **Part 1 – Open session**

4. The Chair welcomed the invited experts: Dr Sanjay Popat , Dr Jesme Fox and Mrs Carole Davies to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
  - 6.1. Dr Ian Bernstein, David Chandler, Gail Coster, Dr Nigel Langford, Dr Iain Miller, Dr Paul Miller, Professor Eugene Milne, Professor Stephen O'Brien, Professor Andrew Renahan, Dr Peter Selby Prof Matt Stevenson, Dr Judith Wardle, Professor Robert Walton and Dr Paul Tappenden all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.
  - 6.2. Professor Stephen O'Brien declared a non-personal specific financial interest. Over the last 12 months he have received support from Bristol-Myers Squibb (EHA 2015 and ASH 2015). The support that was required was for 'booking and payment of reasonable accommodation, meals and travel to attend meetings and conferences. Over the last 12 months my University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb . Professor O'Brien also stated he does not hold any stock in any of the companies concerned nor any position of employment
    - 6.2.1 It was agreed that this declaration would not prevent Professor Stephen O'Brien from participating in this section of the meeting.
7. The Chair asked all NICE Staff to declare any relevant interests.
  - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.
8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for

previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

8.2. Dr Sanjay Popat declared a personal non-specific financial interest as he has done consultancy work for Bristol-Myers Squibb Pharmaceuticals

8.2.1. It was agreed that this declaration would not prevent 8.2. Dr Sanjay Popat from participating in this section of the meeting

9. The Chair introduced the lead team, Dr Iain Miller, Dr Peter Selby and Dr Judith Wardle who gave presentations on the clinical effectiveness and cost effectiveness of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

.

10. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Date, time and venue of the next meeting**

17. Wednesday 11 May 2016, 10:00 and to 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.